BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Deferred Revenue
Payments received for goods or services the company will deliver within the next year.
BioAge Labs, Inc.NASDAQ: BIOA
Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026
Deferred revenue falls 24.3% from a year ago
Deferred revenue stood at $6.19M at the end of Q1 FY2026, down 24.3% from a year earlier and up 7.6% from the prior quarter.
Context
- Deferred revenue amounted to 1.6% of total assets at the end of Q1 FY2026, down 0.8 pp from a year earlier.
- Deferred revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether deferred revenue keeps falling in the next quarterly balance sheet after a -24.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue history
USD · from the balance sheet
- Latest · FY2025
- 5.75M USD
- Year-over-year change
- -26.5%
| Period | Period end | Deferred Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.75M | -26.5% |
| FY2024 | 2024-12-31 | 7.83M | +136.2% |
| FY2023 | 2023-12-31 | 3.31M | — |
| FY2022 | 2022-12-31 | 0 | — |
Deferred Revenue vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so deferred revenue is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -24.3% is the 2nd highest of 4, against a peer median of -100.0%.
- Deferred revenue amounts to 1.6% of total assets for BIOA, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $8.66M USD | — | — | 3.7% | |
BIOABioAge Labs, Inc. | Mar 2026 | $6.19M USD | -24.3% | — | 1.6% |
| Mar 2026 | CA$1.27M CAD | +19.2% | -9.9% | 0.2% | |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | -100.0% | +75.6% | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | CA$0 CAD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding BIOA) | — | -100.0% | +32.9% | 0.0% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.